Background: The aim of the study was to review a local treatment protocol for sinonasal mucosal melanoma (SNMM) focusing on triple modality treatment (TMT), that is, neoadjuvant concomitant chemoradiotherapy (CRT) and surgery.
There is no clear consensus on the optimal management of SNMM, although the primary treatment modality is generally considered to be wide surgical excision. Radiation therapy (RT) is sometimes used in the postoperative adjuvant setting to improve locoregional control. 4, 6, [19] [20] [21] [22] [23] According to US guidelines, adjuvant postoperative RT should be considered for stage III disease and is recommended for stage IVA after surgery, but in Australia postoperative RT is recommended only after nonradical surgery. 3 SNMM has a high risk of hematogenous spread, and despite radical surgery of the primary tumor, the majority of patients are ultimately diagnosed with distant metastases (many within the first year after diagnosis) and most SNMM patients succumb to distant metastatic disease. 4, 17, 21, [24] [25] [26] [27] This may suggest that covert micro metastases are present at the time of diagnosis or around the time of the treatment. 28, 29 Arguably, the high rate of distant metastases advocates that other treatment algorithms than postoperative radiotherapy could be more efficacious in this disease. Thus, adjuvant chemotherapy is an additional treatment option. 18, 30, 31 The efficacy of this treatment is, however, unclear and available information is mostly derived from observational studies. 18 A possible benefit from adjuvant chemotherapy is supported by results of a meta-analysis of 423 patients from 39 studies by Gore et al. Patients who received bimodal treatment that included chemotherapy or immunotherapy or both in addition to surgery had a significantly better survival rate than those who received single modality treatment, that is, surgery or chemotherapy alone. 18 Furthermore, a retrospective study from South Korea which included 32 head and neck mucosal melanoma (MM) and a prospective study from China (189 MM, whereof 86 head and neck MM) indicated survival benefits from adjuvant chemotherapy in patients with head and neck MM. 30, 31 The literature concerning the benefit of neoadjuvant CRT treatment for SNMM is very sparse, with the exception of, for example, Amit et al. They did not find any benefits for patients with SNMM treated with either neoadjuvant or adjuvant chemotherapy. They examined 152 patients with SNMM treated with either surgery alone (n = 57), surgery with postoperative RT (n = 73), surgery with postoperative CRT (n = 8), or induction CRT followed by surgery and postoperative RT (n = 14), respectively, and reported 39%, 42%, 47%, and 27% 5-year OS. 29 The lack of convincing data from literature about the benefits for patients with SNMM treated with either neoadjuvant or adjuvant chemotherapy, together with the finding that distant metastasis is the most common cause of treatment failure, highlights the importance of revisiting the current therapeutic approach to SNMM. 17 Our referral center has, since the 1990s, opted for a "triple modality treatment" (TMT) approach, that is, concomitant chemoradiotherapy (CRT) before surgery for patients treated with curative intention after having observed that concomitant cisplatin and accelerated hyperfractionated RT before surgery appeared to be effective in patients with locally advanced SNMM. 32 The aim of this retrospective study was to describe outcome data for a population-based cohort of consecutive patients with SNMM from southern Sweden where the majority of patients treated with curative intention received concomitant CRT prior to surgical recetion, that is, TMT. We report a seemingly favorable outcome for patients receiving TMT compared with the literature.
| METHODS
We retrospectively reviewed medical records of all consecutive patients diagnosed with a SNMM in Southern Sweden and seen at Skåne University Hospital, Lund, a tertiary referral center, between 1 January 2001 and 31 December 2014, where treatment recommendation with curative or palliative intent was presented by a multidisciplinary tumor board (MTB). Ethical approval for the study was granted from the regional Ethical Review Board (2018/745). Data retrieved comprised age, gender, histology, stage and location, as well as diagnosis date, date of onset, WHO performance status, and Charlson/Deyo comorbidity index. 33 All patients were retrospectively restaged according to the 7th TNM edition of the International Union Against Cancer. 34 
| RESULTS
A total of 22 SNMM patients were identified, 12 women and 10 men (median age 68 years, range 51-83). The 5-and 10-year OS rate was 50% and 19%, respectively. Patients with lower stage disease had better survival than higher stage disease (P < .001).
| Patients treated with curative intention
Eighteen patients, 11 women and 7 men (median age 68 years, range 51-83), met the inclusion criteria for treatment with curative intention as recommended by the MTB, that is, had locoregional contained disease and had undergone at least surgical resection with curative intent. Three patients presented with stage III disease, 14 stage IVA, and 1 stage IVB. Patient and treatment characteristics are summarized in Table 1 . Presenting symptoms had a median duration of 3 months (range 0-12), the most common being nasal obstruction and epistaxis.
All patients had a performance status of 0 according to WHO and the median Charlson/Deyo combined comorbidity index (CCI) was 4.5 (range 2-7). 33 The primary tumor was located in the nasal cavity for 11 (61%) patients. Seven patients (39%) had primary tumors with paranasal location, all involving the maxillary sinus, 2 also the nasopharynx, 3 also the orbital floor, and 2 also the skull base (Table 1) Year of diagnosis The median OS for patients treated with curative intention (n = 18) was 69 months (Figure 1 ). The 5-year OS rate was 61% and the 10-year OS 24%, without any correlation between given treatment and OS. The 5-year DFS rate was 33% and the 10-year DFS was 15%. Two of the patients in this cohort had no evidence of disease during long-term follow-up (Table 1) . Of the initial recurrences, four patients recurred only locally, nine with single or multiple distant metastases, and two with local disease and distant metastases. Distant metastases were located in the lung (60%), brain (40%), liver (40%), other viscera (30%), bone (20%), and distant cutis (10%).
| Stage III (n = 3)
None of these patients had recurrences within 12 months and the median OS was 83 months (Table 1 ).
| Stage IVA (n = 14)
The median OS for the 10 patients with stage IVA disease who received neoadjuvant TMT was 69 months (5-year OS 70% and 10-year OS 20%) compared to median 20 months for those that did not receive this (Figure 2 and Table 2 ). The DFS for patients who received neoadjuvant TMT was significantly longer than for those that did not (P = .01) ( 
| Patients treated with palliative intention
Patients treated with palliative intention (n = 4) had very short survival (median OS 6 months) ( Figure 1 ). The first patient had fast local tumor progression after nonradical debulking surgery and then received palliative RT, the second only received palliative RT because of second primary tumor in the lung, the third only nonradical surgery in the orbit because of choosing not to sacrifice the eye. The initial plan for the fourth patient was neoadjuvant TMT, but tumor progression with intracranial involvement inhibited the planned surgery (Table 1 ).
| DISCUSSION
In this retrospective analysis of 22 consecutive patients with SNMM (where also four patients who received palliative treatment intention were included), we observed a 50% 5-year OS, which seemingly is better than the 20%-40% OS rates reported previously. 4, 5, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Our lead finding was a particularly high survival rate in a cohort of 10 stage IVA SNMM treated with neoadjuvant TMT with curative intention:
5-year OS was 70% and 10-year OS 20%. The results warrant attention as they may suggest a favorable survival outcome for a disease with characteristically poor prognosis.
Cancer cells circulating in the blood represent a mechanism by which a tumor can metastasize, and trauma to a tumor, for example, caused by piecemeal resection, may increase their numbers. 35, 36 Accordingly, it is established that cancer cell implantation can occur at sites remote from a primary tumor due to surgery. 37 The high rate of distant metastases in patients who succumb to SNMM, verified in this study, may of course reflect that covert micrometastases are present at the time of diagnosis, but a mechanism involving release of cancer cells into the blood caused by a surgery may also be considered. 28, 29 An inferred hypothesis is that concomitant CRT before surgery for SNMM, that is, TMT, reduces the risk that circulating cancer cells produce metastases. 37 Neoadjuvant CRT may be particularly important in well-vascularized areas such as the sinonasal region where gross en bloc resection sometimes is not possible and piecemeal surgery is performed either with endoscopic or open transfacial approaches. The high 5-year OS rate (70%) observed in our study for patients with stage IVA disease who received neoadjuvant TMT with curative intention may reflect that this regimen indeed adjourns the establishment of metastases. In agreement, the fact that only one patient in this cohort suffered from local recurrence during the first 5 years of follow-up, represented by a 90% 5-year local RFS, is promising as local failure is considered to be a harbinger of metastatic disease. 24 However, all but two patients who received neoadjuvant TMT eventually succumbed to the melanoma disease, which suggests that this treatment regimen might merely have delayed the onset of metastatic disease.
There is a sparsity of literature on neoadjuvant CRT in SNMM. 29 In contrast to our findings, Amit et al did not find any benefits for patients with SNMM treated with neoadjuvant CRT. 29 In their study, 152 patients with SNMM were treated with either surgery alone, surgery with postoperative RT, surgery with postoperative CRT, or induction CRT followed by surgery and postoperative RT. They reported 5-year OS rate of only 27% for the last cohort which included 14 patients. 29 In our cohort, the 10 patients with stage IVA disease who received TMT with curative intention had a higher survival rate Malignant melanoma is traditionally regarded as more resistant to RT than many other cancers and a reason may be that the disease features extremely effective sublethal repair mechanisms. 20 In addition, a particular challenge with regard to RT for SNMM is that the tumors are located in anatomical sites surrounded by important radiosensitive structures. There are several studies suggesting that adjuvant RT improves local control in SNMM, 4, 6, [19] [20] [21] 26, 38 whereas positive effects on survival has been observed infrequently. 8, 39 In our study, the Also, because no patient with SNMM is staged lower than stage III, this is in accordance with the present adjuvant treatment protocols for patients with cutaneous malignant melanoma (≥stage III).
| CONCLUSION
We found a seemingly higher survival rate for SNMM patients treated with curative intention than reported in the literature. Our findings which should be interpreted with caution given the small number of patients in the study, suggest the potential that patients with advanced SNMM (stage IVA) may benefit from concomitant neoadjuvant CRT before surgery. The results emphasize a need for prospective studies with appropriate comparison groups focusing on adjuvant therapies before and/or after surgery for curatively intended treatments of SNMM.
